NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

尿失禁治療藥市場 - 市場規模,佔有率,預測,機會分析:2020年∼2027年

Urinary Incontinence Treatment Drugs Market, by Incontinence Type, by Drug Class, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 995632
出版日期 內容資訊 英文 180 Pages
商品交期: 2-3個工作天內
價格
尿失禁治療藥市場 - 市場規模,佔有率,預測,機會分析:2020年∼2027年 Urinary Incontinence Treatment Drugs Market, by Incontinence Type, by Drug Class, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2021年02月18日內容資訊: 英文 180 Pages
簡介

尿失禁是尿路發生各種異常,結果發生排尿。尿失禁治療藥市場,由於尿失禁疾病的盛行率增加,在預測期間內預計促進市場成長。

本報告提供全球尿失禁治療藥市場相關調查分析,市場概要,市場規模與預測,各市場區隔的市場分析,各地區的市場分析,競爭情形等相關的系統性資訊。

目錄

第1章 調查目的與前提條件

第2章 市場概要

第3章 市場動態、規定、趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 主要的發展
  • 法規方案
  • 新推出與核准
  • 開發平台分析
  • PEST分析
  • 流行病學

第4章 COVID-19的影響分析

  • 供給方面分析
  • 需求面分析
  • 醫療產業的影響

第5章 全球尿失禁治療藥市場:失禁的各類型

  • 簡介
  • 急性尿失禁
  • 應力性尿失禁
  • 溢流性尿失禁
  • 混合性尿失禁
  • 其他

第6章 全球尿失禁治療藥市場:各藥物分類

  • 簡介
  • 抗膽鹼促效劑/解痙藥
  • 骨骼肌肉鬆弛劑
  • 抗憂鬱症藥
  • Alpha阻斷劑
  • 局部雌激素
  • 其他

第7章 全球尿失禁治療藥市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第8章 全球尿失禁治療藥市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東
  • 非洲

第9章 競爭情形

  • 企業簡介
    • Johnson & Johnson
    • Pfizer Inc.
    • Astellas Pharma, Inc.
    • Allergan, Inc.
    • Takeda Pharmaceutical Company Limited
    • Merck & Co., Inc.
    • Sanofi SA

第10章 Section

目錄

Title:
Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Urinary incontinence is considered to be the variety of abnormalities occurs in the urinary tract that results in to experiencing normal micturition. This leads to involuntary loss of bladder control. Approximately 40% of community-dwelling elderly and hospitalized patients are afflicted with this disorder and the remaining 60% of nursing home patients experience this disorder, and it is often the reason for their admittance. The causes of urinary incontinence are numerous and involves age-related changes in the bladder and urethra, including decline in outlet resistance in females and prostate enlargement in males.

In urinary incontinence, muscles around urethra do not work in the way they should, resulting in leak-out of urine. There are various types of incontinences such as stress (bladder is under pressure), urge (intense urge to pass urine), and overflow (chronic urinary retention). The severity of urinary incontinence varies as per health conditions such as urinary tract infection (UTI), constipation, and age group, as urinary incontinence is found more in geriatric population.

Market Dynamics

The urinary incontinence treatment drugs market is expected to drive the market growth during the forecast period, owing to increasing prevalence of urinary incontinence disease. For instance, according to American Urological Association (AUA) 2017 report, more than 200 million people worldwide were affected with stress urinary incontinence (SUI) in 2017, which can seriously affect the quality of life of both men and women. As a disease whose prevalence is related to advancing age, it affects more women than men with an approximate ratio of 3: 1.

Key features of the study:

  • This report provides in-depth analysis of the global urinary incontinence treatment drugs market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global urinary incontinence treatment drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, government initiatives, technological upgradation, market expansion, and marketing tactics
  • The global urinary incontinence treatment drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the urinary incontinence treatment drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Urinary Incontinence Treatment Drugs Market, By Incontinence Type:
  • Urge Incontinence
  • Stress Incontinence
  • Over-flow Incontinence
  • Mixed Incontinence
  • Other Type
  • Global Urinary Incontinence Treatment Drugs Market, By Drug Class:
  • Anticholinergic/Antispasmodic Agents
  • Skeletal Muscle Relaxants
  • Antidepressants
  • Alpha Blockers
  • Topical Estrogens
  • Others
  • Global Urinary Incontinence Treatment Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Urinary Incontinence Treatment Drugs Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
    • By Incontinence Type:
  • Urge Incontinence
  • Stress Incontinence
  • Over-flow Incontinence
  • Mixed Incontinence
  • Other Type
    • By Drug Class:
  • Anticholinergic/Antispasmodic Agents
  • Skeletal Muscle Relaxants
  • Antidepressants
  • Alpha Blockers
  • Topical Estrogens
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Europe
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
    • By Incontinence Type:
  • Urge Incontinence
  • Stress Incontinence
  • Over-flow Incontinence
  • Mixed Incontinence
  • Other Type
    • By Drug Class:
  • Anticholinergic/Antispasmodic Agents
  • Skeletal Muscle Relaxants
  • Antidepressants
  • ALPHA Blockers
  • Topical Estrogens
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Asia Pacific
    • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
    • By Incontinence Type:
  • Urge Incontinence
  • Stress Incontinence
  • Over-flow Incontinence
  • Mixed Incontinence
  • Other Type
    • By Drug Class:
  • Anticholinergic/Antispasmodic Agents
  • Skeletal Muscle Relaxants
  • Antidepressants
  • Alpha Blockers
  • Topical Estrogens
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
    • By Incontinence Type:
  • Urge Incontinence
  • Stress Incontinence
  • Over-flow Incontinence
  • Mixed Incontinence
  • Other Type
    • By Drug Class:
  • Anticholinergic/Antispasmodic Agents
  • Skeletal Muscle Relaxants
  • Antidepressants
  • Alpha Blockers
  • Topical Estrogens
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
    • By Incontinence Type:
  • Urge Incontinence
  • Stress Incontinence
  • Over-flow Incontinence
  • Mixed Incontinence
  • Other Type
    • By Drug Class:
  • Anticholinergic/Antispasmodic Agents
  • Skeletal Muscle Relaxants
  • Antidepressants
  • Alpha Blockers
  • Topical Estrogens
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
    • By Incontinence Type:
  • Urge Incontinence
  • Stress Incontinence
  • Over-flow Incontinence
  • Mixed Incontinence
  • Other Type
    • By Drug Class:
  • Anticholinergic/Antispasmodic Agents
  • Skeletal Muscle Relaxants
  • Antidepressants
  • Alpha Blockers
  • Topical Estrogens
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Company Profiles
    • Johnson & Johnson
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
    • Pfizer Inc.
    • Astellas Pharma, Inc.
    • Allergan, Inc.
    • Takeda Pharmaceutical Company Limited
    • Merck & Co., Inc.
    • Sanofi S.A.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Incontinence Type
    • Market Snippet, By Drug Class
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • New Lunches and Approvals
  • Pipeline Analysis
  • PEST Analysis
  • Epidemiology

4. Impact Analysis of Covid-19

  • Supply side Analysis
  • Demand Side Analysis
  • Impact on Healthcare Industry

5. Global Urinary Incontinence Treatment Drugs Market, By Incontinence Type, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Urge Incontinence
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Stress Incontinence
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Over-flow Incontinence
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Mixed Incontinence
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Other Type
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Urinary Incontinence Treatment Drugs Market, By Drug Class, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Anticholinergic/Antispasmodic Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Skeletal Muscle Relaxants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Antidepressants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Alpha Blockers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Topical Estrogens
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Urinary Incontinence Treatment Drugs Market, By Distribution Channel, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

8. Global Urinary Incontinence Treatment Drugs Market, By Region, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Incontinence Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Incontinence Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Latin America
    • Market Size and Forecast, By Incontinence Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Asia Pacific
    • Market Size and Forecast, By Incontinence Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Incontinence Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Incontinence Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

  • Company Profiles
    • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Astellas Pharma, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Allergan, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact